UPDATE - Canaccord Genuity Downgraded United Therapeutics (UTHR) to Hold; Sidelined on Uncertainty
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $521.00 --0%
Rating Summary:
17 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
17 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
UPDATE - Canaccord Genuity downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold, price target lowered from $56 to $44.
Analyst, Salveen Richter, said, "While the company continues to be a solid cash-generation story, it faces the following challenges: 1) generic threats to Remodulin and Adcirca; 2) the uncertainty of oral treprostinil securing FDA approval in a monotherapy setting on its October 27 PDUFA (one positive P3 monotherapy and two failed P3 combination studies); 3) even if approved, the market potential of oral treprostinil is likely to be limited given physicians’ concern on the magnitude of benefit and their preference for combination use; 4) potential competition from ATLN’s macitentan (P3 SERAPHIN data expected in Q2/12; mortality/morbidity); and 4) a lack of near-term value-driving catalysts."
Lowers FY14 GAAP EPS estimate from $4.89 to $4.21.
Analyst, Salveen Richter, said, "While the company continues to be a solid cash-generation story, it faces the following challenges: 1) generic threats to Remodulin and Adcirca; 2) the uncertainty of oral treprostinil securing FDA approval in a monotherapy setting on its October 27 PDUFA (one positive P3 monotherapy and two failed P3 combination studies); 3) even if approved, the market potential of oral treprostinil is likely to be limited given physicians’ concern on the magnitude of benefit and their preference for combination use; 4) potential competition from ATLN’s macitentan (P3 SERAPHIN data expected in Q2/12; mortality/morbidity); and 4) a lack of near-term value-driving catalysts."
Lowers FY14 GAAP EPS estimate from $4.89 to $4.21.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- HomeTrust Bancshares (HTB) PT Raised to $57 at Stephens
- Advance Auto Parts (AAP) PT Lowered to $47 at UBS as Demand Environment Remains Tough
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
